Mario Balsa· @MarioBalsaMD · X·· 2 days agoScore70
Body
🚨 My top 4 #Melanoma #ESMO26 GC101 TIL: TILs without the full toxicity baggage?
Randomized phase II in >=2L anti-PD-1-resistant melanoma! Notably 73% acral/mucosal!!!
▪️PFS: 4.37 vs 1.61m (HR 0.44)
💥 ORR: 44% vs 8%
-Acral: ORR 45% vs 8%
-Mucosal: ORR 50% vs 0%
IL-2-free + reduced-intensity lymphodepletion 👀 and the discussant questioned whether 50% dose sintilimab really changes much…
@OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma
900 views · 10 likes · 7 reposts · 2 replies
Replies in this thread
- Lude@Lude2025
@MarioBalsaMD @kainvests @Larvol @brunolarvol @SuyogCancer What about Iovance Amtagvi that’s an incredible drug curing cancer
- ONCO BRUNO@brunolarvol
@MarioBalsaMD @Larvol @SuyogCancer Hope we get to say hi 👋
Source: Mario Balsa · x.com